India Radioligand Therapy (RLT) – A New Era in Targeted Cancer Care
Radioligand Therapy (RLT) in India is emerging as a promising form of precision oncology. This therapy uses targeted radioactive molecules that bind specifically to cancer cells, delivering radiation directly to tumors while sparing healthy tissues. India's oncology centers have increasingly adopted RLT for difficult-to-treat cancers such as neuroendocrine tumors and prostate cancer. Patients benefit from fewer side effects compared to conventional chemotherapy and improved quality of life.
RLT’s growing recognition is supported by increasing nuclear medicine capabilities, expanded isotope availability, and advanced radiopharmaceutical production facilities across India. Specialist doctors emphasize its value as part of a personalized treatment plan, particularly for metastatic cases where options are limited. With improved infrastructure and awareness, RLT is expected to become a major component of India's cancer treatment ecosystem.